文献速递生殖医学

口服醋酸甲羟孕酮在体外受精中用于排卵抑制:一项队列试验

Oral medroxyprogesterone acetate for the use of ovulation suppression in in vitro fertilization: a cohort trial.
PubMed 文献 · Fertil Steril · 2024-01-20

该队列试验比较了口服醋酸甲羟孕酮(MPA)与促性腺激素释放激素(GnRH)拮抗剂在体外受精(IVF)刺激周期中的排卵抑制效果,MPA组418例,对照组419例历史周期。结果显示MPA组无提前排卵病例,获卵数、囊胚数、整倍体囊胚数及临床妊娠率与对照组无显著差异,且MPA组药物费用节省、监测次数和注射次数减少。

要点

  • MPA组无提前排卵,对照组5例(0% vs 1.2%;RR=0.09;95%CI 0.01-1.66)。
  • 获卵数、囊胚数、整倍体囊胚数及临床妊娠率两组无显著差异。
  • MPA组平均节省药物费用491±119美元,监测次数减少1次,每周期注射次数减少5.0±1.2次。

核心结论

  • 在IVF周期中,MPA能有效抑制排卵,周期结局和生殖结局与拮抗剂方案相似,并具有节省费用、减少就诊次数和注射次数的额外优势。

研究设计与样本

  • 队列试验,单中心学术附属私人生育诊所,纳入2020年至2023年接受自体IVF、年龄18-44岁、所有诊断的患者。
  • MPA组为418例接受MPA方案卵巢刺激的患者(前瞻性收集数据),对照组为419例历史性GnRH拮抗剂周期。

主要发现

  • MPA组无提前排卵病例,对照组共5例(0% vs 1.2%;RR=0.09;95%CI 0.01-1.66)。
  • 获卵数(14.3±10.2 vs 14.3±9.7;P=.83)、囊胚数(4.9±4.6 vs 5.0±4.6;P=.89)、整倍体囊胚数(2.4±2.6 vs 2.2±2.4;P=.18)在MPA组与对照组间无差异。
  • 临床妊娠率两组相似(70.4% vs 64.2%;RR=0.92;95%CI 0.72-1.18)。
  • IVF刺激时长或刺激药物剂量无差异。
  • MPA组平均节省药物费用491±119美元,平均监测访视次数少1次(4.4±0.9 vs 5.6±1.1;P<.01),每周期注射次数少5.0±1.2次。

临床怎么用

  • 对于IVF周期中的排卵抑制,MPA可有效预防排卵,且周期结局和生殖结局与拮抗剂方案相似,并可能节省费用、减少就诊次数和注射次数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To broadly assess the efficacy of medroxyprogesterone acetate (MPA) for ovulatory suppression during in vitro stimulation compared with gonadotropin-releasing hormone (GnRH) antagonist cycles. DESIGN: Cohort trial. SETTING: A single academic-affiliated private fertility practice. PATIENTS: Patients of all diagnoses aged 18-44 years undergoing autologous in vitro fertilization (IVF) for fertility treatment between 2020 and 2023. INTERVENTIONS: Comparison of MPA vs. antagonist IVF stimulation cycles. MAIN OUTCOME MEASURES: Rates of premature ovulation, oocyte and embryo yield, embryo quality, pregnancy rates, and logistical benefits. RESULTS: Prospective data was collected on 418 patients who underwent MPA protocol ovarian stimulation (MPA group), which was compared with 419 historical control gonadotropin hormone-releasing hormone antagonist cycles (control group). Age was similar between groups (35.6 ± 4.6 vs. 35.7 ± 4.8 years; P = .75). There were no cases of premature ovulation in the MPA group compared with a total of five cases in the control group (0% vs. 1.2%; risk ratio [RR] = 0.09; 95% confidence interval [CI], 0.01, 1.66). No differences were seen between number of oocytes retrieved (14.3 ± 10.2 vs. 14.3 ± 9.7; P = .83), blastocysts (4.9 ± 4.6 vs. 5.0 ± 4.6; P = .89), or euploid blastocysts (2.4 ± 2.6 vs. 2.2 ± 2.4; P = .18) in the MPA vs. control group respectively. Clinical pregnancy rate was similar between groups (70.4% vs. 64.2%; RR = 0.92; 95% CI, 0.72, 1.18). There was no difference in length of IVF stimulation or dose of stimulation medications. Patients in the MPA group saved an average of $491 ± $119 on medications, had an average of one less monitoring visit (4.4 ± 0.9 vs. 5.6 ± 1.1; P<.01), and 5.0 ± 1.2 less injections per cycle. When adjusting for age and ovarian reserve, protocol group (MPA vs. control) did not influence having an embryo available for transfer (76.6% vs. 73.4%; adjusted RR = 1.05; 95% CI, 0.94, 1.14). CONCLUSION: For ovulatory suppression during IVF cycles, MPA was effective at preventing ovulation while demonstrating similar cycle and reproductive outcomes, with the additional benefits of patient cost savings, increased convenience with decreased number of visits, and fewer injections.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Welp AM, Williams CD, Smith LP, et al. Oral medroxyprogesterone acetate for the use of ovulation suppression in in vitro fertilization: a cohort trial. Fertil Steril. 2024. PMID: 38253117. doi:10.1016/j.fertnstert.2024.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。